Morningstar

Teva Pharmaceutical Industries Ltd ADR TEVA

Morningstar Rating
Unlock
Stock XNYS Rating as of
$17.46 −0.28 (1.58%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Teva: Simlandi to See Share Gains in a Growing Humira Biosimilar Market Thanks to Formulary Update

Keonhee Kim

Cigna’s Express Scripts announced this week that it is dropping branded Humira from its 2025 commercial formularies and replacing it with biosimilar options from Boehringer Ingelheim, Sandoz, and Teva. This follows a similar move by CVS Caremark, which removed branded Humira from its major formularies in April. From a biosimilar manufacturers standpoint, we think this is a favorable move from the second-largest specialty pharmacy in the country; according to Drug Channels, Cigna’s specialty pharmacy makes up about one quarter of US specialty prescription revenue.

Read Full Report

Price vs Fair Value

View History
TEVA is trading at a 741% premium.
Price
$17.46
Fair Value
$91.00
Uncertainty
High
1-Star Price
$29.48
5-Star Price
$33.60
Economic Moat
Tnqs
Capital Allocation
Pfclrrk

Bulls Say, Bears Say

Bulls

New products including Ajovy, Austedo, and Uzedy will fuel Teva’s top and bottom lines as their adoption increases.

Bears

The majority of Teva's business lies in generic and off-patent branded drugs and faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply chain exert force.

Show More

News

View All

Trading Information

Previous Close Price
$17.74
Day Range
$17.41–17.74
52-Week Range
$8.06–19.08
Bid/Ask
$17.46 / $17.49
Market Cap
$19.78 Bil
Volume/Avg
5.5 Mil / 8.5 Mil

Key Statistics

Price/Earnings (Normalized)
6.49
Price/Sales
1.20
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Value
Total Number of Employees
37,851
Website
https://www.tevapharm.com

Competitors

Valuation

View More
Metric
TEVA
SDZ
VTRS
Price/Earnings (Normalized)
 6.4920.254.18
Price/Book Value
 3.112.010.71
Price/Sales
 1.201.690.91
Price/Cash Flow
 12.3721.854.35
Price/Earnings
TEVA
SDZ
VTRS

Financial Strength

Metric
TEVA
SDZ
VTRS
Quick Ratio
 0.460.610.65
Current Ratio
 0.891.221.53
Interest Coverage
 0.830.78−0.13
Quick Ratio
TEVA
SDZ
VTRS

Profitability

Metric
TEVA
SDZ
VTRS
Return on Assets (Normalized)
 7.18%4.37%7.02%
Return on Equity (Normalized)
 43.52%9.95%16.41%
Return on Invested Capital (Normalized)
 13.87%9.73%9.80%
Return on Assets
TEVA
SDZ
VTRS

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
DkthrtdcRmzcb$88.3 Bil
 Merck KGaA ADR
MKKGY
MnksvvxmrQqytmzt$78.0 Bil
 Haleon PLC ADR
HLN
WscnctfsgTrntd$48.4 Bil
 Viatris Inc
VTRS
XgqdzkgqvJvj$13.8 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
TlmdryzGbmch$13.5 Bil
 Catalent Inc
CTLT
MbxykmyVbllhx$10.9 Bil
 Prestige Consumer Healthcare Inc
PBH
VtlgkptwVnlxqk$3.5 Bil
 Perrigo Co PLC
PRGO
GbjccydxPkq$3.5 Bil
 Green Thumb Industries Inc
GTBIF
SjbyqxyyvBclwb$2.5 Bil
 Curaleaf Holdings Inc
CURLF
ZrbtqkldNpcj$2.3 Bil

Sponsor Center